Welcome to our dedicated page for CRYO CELL INTERNATIONAL SEC filings (Ticker: CCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cryo-Cell International filings document material events, governance matters, financing arrangements and exchange-listing compliance for a cord blood banking and cryogenic storage company. Recent 8-K reports cover NYSE American continued-listing standards, dividend determinations, annual meeting timing, and Regulation FD disclosures tied to company announcements.
The filing record also includes definitive proxy materials for director elections, auditor ratification, executive compensation voting and stockholder meeting procedures. Financing disclosures describe amendments to the company’s Susser Bank credit agreement, including revolving credit and term loan arrangements, subsidiary guarantor provisions involving Celle Corp., maturity terms, interest-rate mechanics and related security documents.
Cryo-Cell International Inc. director, Chairman and Co-CEO David Portnoy reported updated holdings and new equity awards. On January 7, 2026, he was granted two direct stock option awards: one for 50,000 shares and another for 150,000 shares of common stock, both with an exercise price of $3.89 per share and expirations in 2031.
The 50,000 options vest in three equal parts: upon grant, on January 7, 2027, and on January 7, 2028. The 150,000 options, granted under the Cryo-Cell 2022 Stock Incentive Plan, are split into three equal tranches that each require both time-based service and stock-price performance hurdles of $6, $8, and $10 per share, each measured over 20 consecutive trading days after the first, second, and third anniversaries of grant.
Cryo-Cell International's Chief Information Officer, Oleg Mikulinsky, reported new equity awards and existing holdings. On January 7, 2026, he received two grants of stock options on the company’s common stock at an exercise price of $3.54 per share, one for 10,000 options that vest in thirds on January 7, 2026, 2027 and 2028, and another for 20,000 options granted under the Cryo-Cell 2022 Stock Incentive Plan with three tranches tied to both time and stock-price performance hurdles at $6, $8, and $10 per share over specified 20-day periods. He also reports direct ownership of 104,349 common shares and several prior option awards with varying exercise prices and vesting schedules.
Cryo-Cell International Co-CEO Mark Portnoy reported new stock option grants and updated his holdings in company securities. On January 7, 2026, he was granted a stock option for 50,000 shares of common stock at an exercise price of $3.89 per share, expiring on January 7, 2031. This grant, made under the Cryo-Cell 2022 Stock Incentive Plan, is split into three equal tranches that each require both time-based vesting and stock price hurdles of $6, $8, and $10 per share over 20 consecutive trading days.
Portnoy also received a separate stock option for 25,000 shares at an exercise price of $3.89 per share, expiring January 7, 2031, which vests one-third upon issuance, one-third on January 7, 2027, and one-third on January 7, 2028. Following these grants, he reports 821,973 common shares held directly, 42,266 shares held indirectly via a 401(k), and 71,529 shares held indirectly by Capital Asset Fund #1 Limited Partnership, where he may be deemed a beneficial owner as general partner.
Cryo-Cell International disclosed new equity awards to its VP Finance and CFO, Jill M. Taymans. On January 7, 2026, she received two stock option grants at an exercise price of $3.54 per share. One grant covers 10,000 options that vest one-third on the grant date, one-third on January 7, 2027, and one-third on January 7, 2028. The second grant covers 20,000 options under the Cryo-Cell 2022 Stock Incentive Plan, split into three equal tranches that each require both time-based vesting and the stock reaching average closing prices of at least $6, $8, and $10 per share over 20 consecutive trading days, tied to the first, second, and third anniversaries of the grant. Taymans also reports 45,396 shares of common stock owned directly and multiple prior option awards with expirations ranging from 2026 to 2031.
Cryo-Cell International (CCEL) Chairman and Co-CEO David Portnoy filed a Form 4 reporting open-market purchases of common stock. On 11/20/2025, he acquired 289 shares at $4.00 per share, and on 11/21/2025 he acquired 800 shares at $4.04 and additional shares at $4.09 and $4.10, including purchases held as custodian for his son. Following these transactions, his directly held common stock increased to 847,629 shares, with additional indirect holdings through family accounts and various entities.
The filing also lists several stock option grants over prior years with exercise prices between $4.30 and $12.27, covering amounts such as 280,000 and 50,000 underlying shares, and expirations from 2027 to 2030. Some options vest over time on specified future dates, while one grant vests in full if the company’s share price reaches $25.00 during its seven-year term.
Cryo-Cell International (CCEL) director, 10% owner, and Chairman/Co-CEO David Portnoy reported open-market purchases of the company’s common stock. He bought 1,429 shares at $4.00 on 11/17/2025, 640 shares at $4.09 on 11/18/2025, and 1,921 shares at a weighted average price of $4.08 on 11/19/2025.
Following these transactions, he directly beneficially owns 846,540 common shares and also reports additional indirect holdings through various entities and family accounts. He further holds several stock option awards, including grants exercisable at prices ranging from $4.30 to $12.27 per share with expirations between 2027 and 2030 and vesting schedules tied to time and, in one case, the stock reaching $25.00 per share.
Cryo-Cell International (CCEL) insider David I. Portnoy (Director, 10% Owner, Chairman, Co-CEO) reported open-market purchases of common stock. He acquired 1,026 shares at $4.18 on 11/10/2025, 2,474 shares at a weighted average price of $4.13 on 11/11/2025, and 2,040 shares at a weighted average price of $4.12 on 11/12/2025. Following these trades, his direct beneficial ownership stands at 842,550 shares.
He also reports derivative holdings, including 280,000 stock options at $12.27 expiring 12/22/2028, which vest immediately if the stock reaches $25 during the seven-year term.
Cryo-Cell International (CCEL) announced it will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. The company stated that future dividends may or may not be paid, with decisions driven by financial performance, capital requirements, and strategic priorities.
This update signals a pause in cash distributions for Q4 FY2025 and places emphasis on deploying resources based on operating needs and strategic plans. The company’s stance leaves flexibility for future payouts if conditions align with its financial and strategic criteria.
Cryo-Cell International (CCEL) reported insider purchases by Chairman and Co-CEO David I. Portnoy. He acquired 4,666 shares of common stock on 10/31/2025 at $4.45 and 5,000 shares on 11/04/2025 at a weighted average price of $4.40.
Following these transactions, Portnoy beneficially owned 837,010 shares directly. He also reports additional indirect holdings through entities and family accounts, as listed in the filing.
Cryo-Cell International (CCEL) amended its credit facilities with Susser Bank. The Fifth Amendment adds wholly owned subsidiary Celle Corp. as a guarantor and updates key terms of the company’s revolving credit facility and term loan.
The revolving credit facility’s commitment was revised to $8,000,000 and its maturity extended to October 18, 2027. The term loan maturity was extended to July 29, 2032. The amendment also sets revised pricing: Base Rate margins of 4.25% for term loans and 3.75% for revolving loans, Monthly SOFR margins of 3.25% for term loans and 2.75% for revolving loans, and a 0.25% commitment fee.
Existing rate constructs and floors remain in place from the 2022 agreement, with the company able to elect Base Rate or Monthly SOFR-based interest. The changes extend maturities while reducing revolver capacity, and add collateral support via a Security Agreement benefiting the lenders.